$ 30 billion in half a year!Pfizer's new crown vaccine and new crown medicine are sold crazy

On July 28, Pfizer announced the results of the first half of 2022. The revenue created by the new crown vaccine and the new crown oral medication accounts for more than half of Pfizer's total revenue.

Pfizer CEO Albert Bourla said at the financial report interpretation meeting on the same day: "Pfizer's advantage is not in the field of government procurement." In addition to the MRNA new crown vaccine and the new crown special medicine Paxlovid, Pfizer's other varieties are also very very very very very very very very very very very very very well -with. Look at it.

Behind this statement reflects Pfizer's concerns about the shrinking of the new crown vaccine and drug orders.

In the first half of this year, Pfizer achieved a total of US $ 53.4 billion in operating income, of which MRNA vaccine contributed $ 22.075 billion, and the new crown special medicine contributed $ 9.585 billion. The total amount of the two exceeded 31.5 billion US dollars, accounting for 59%of the total revenue.

However, in terms of products, the global epidemic relief and the increase in vaccination rate have affected the sales of the MRNA vaccine. In the second quarter of this year, Pfizer MRNA's new crown vaccine sold $ 8.1 billion, a decrease of about 50%from the first quarter.

Pfizer CEO repeatedly emphasized at the interpretation meeting that the new crown epidemic is still the biggest challenge of the world's health. "We also hope that the epidemic will end soon, but this is unscientific." At the same time, Pfizer maintains the sales forecast of the new crown vaccine and special effects drugs throughout the year, that is, Vaccine sales are $ 22 billion, and special effects drug sales are 32 billion US dollars.

So far, Paxlovid, the new crown, is still purchased by the government in the United States and provided them for free. The main sales channels are hospitals. In April this year, the US government just signed a new order of 20 million new crowns with Pfizer. As of July 15, there were 41,000 supply points in the United States.

However, in order to achieve the goal of "annual sales of $ 32 billion", Pfizer has been advocating that "FDA is expected to liberalize patients to buy new crowded effect medicines by themselves in the near future."

Pfizer CEO said at the interpretation meeting that he is closely in contact with officials in many states, hoping to push Paxlovid for sale in pharmacies in some states.

### ###

- END -